More Investment in Pear Therapeutics to Accelerate Reimbursement Coverage for Digital CBT-I
A new strategic investor is investing $20 million in Pear Therapeutics, bringing the total Series D investment to $100 million.
A new strategic investor is investing $20 million in Pear Therapeutics, bringing the total Series D investment to $100 million.
A retrospective analysis found a discrepancy between self-reported perception and objective readings in all sleep disorders.
In the two years since FDA clearance for the device, the sleep physician-founder has new insights...
Highlights include an oral presentation focusing on the long-term efficacy and safety of DAYVIGO in adults ages 65 and older with insomnia disorder from the Phase 3 clinical study.
Consumer Reports reviews tips to help readers stay asleep throughout the entire night. Try to go to bed and get up at about the same time each day to get your body used to a fixed sleep schedule. And make sure that you’re...
Geriatric populations are simultaneously more likely to have insomnia and less likely to tell their medical team about it.
The double whammy of co-occurring insomnia and obstructive sleep apnea (OSA) is a complex problem best managed with non-drug targeted psych interventions, an Australian study has found.